5878 Federal Register / Vol. 65, No. 25 / Monday, February 7, 2000 / Notices

limitations imposed by the review and

funding cycle.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: February 13, 2000.

Time: 7:00 PM to 9:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn, Bethesda, MD 20814.

Contact Person: Dennis Leszczynski,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 6170,

MSC 7892, Bethesda, MD 20892, (301) 435–

1044.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Pathophysiological

Sciences Initial Review Group, General

Medicine A Subcommittee 2.

Date: February 14–15, 2000.

Time: 8:00 AM to 6:00 PM.

Agenda: To review and evaluate grant

applications.

Place: The Washington Monarch Hotel,

2401 M Street, NW, Washington, DC 20037.

Contact Person: Mushtaq A. Khan, DVM,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 2176,

MSC 7818, Bethesda, MD 20892, 301–435–

1778, khanm@csr.nih.gov.

This notice is being published less than 15

days prior to the meeting due to the timing

lmitations imposed by the review and

funding cycle.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: February 14, 2000.

Time: 8:00 AM to 12:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Georgetown Holiday Inn,

Washington, DC 20007.

Contact Person: Dharam S. Dhindsa,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5126,

MSC 7854, Bethesda, MD 20892, (301) 435–

1174, dhindsad@csr.nih.gov.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Endocrinology and

Reproductive Sciences Initial Review Group,

Reproductive Endocrinology Study Section.

Date: February 14–15, 2000.

Time: 8:00 AM to 3:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Gaithersburg Hilton, 620 Perry

Parkway, Gaithersburg, MD 20877.

Contact Person: Abubakar A. Shaikh,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 6166,

MSC 7892, Bethesda, MD 20892, (301) 435–

1042.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Health Promotion and

Disease Prevention Initial Review Group,

Alcohol and Toxicology Subcommittee 3.

Date: February 14–15, 2000.

Time: 8:00 AM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Washington Monarch Hotel, 2401 M

Street, NW, Washington, DC 20037.

Contact Person: Christine Melchior,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 4102,

MSC 7816, Bethesda, MD 20892, (301) 435–

1713.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Health Promotion and

Disease Prevention Initial Review Group

Nursing Research Study Section.

Date: February 14–16, 2000.

Time: 8:30 AM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn—Silver Spring, 8777

Georgia Avenue, Silver Spring, MD 20910.

Contact Person: Getrude McFarland,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 4110,

MSC 7816, Bethesda, MD 20892, (301) 435–

1784.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Musculoskeletal and

Dental Sciences Initial Review Group General

Medicine A Subcommittee 1.

Date: February 14–15, 2000.

Time: 8:30 AM to 4:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Hyatt Regency Bethesda, One

Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Harold M. Davidson,

Center for Scientific Review, National

Institutes of Health, 6701 Rockledge Drive,

Room 4216, MSC 7814, Bethesda, MD 20892,

(301) 435–1776, davidsoh@csr.nih,gov.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Endocrinology and

Reproductive Science Initial Review Group

Endocrinology Study Section.

Date: February 14–15, 2000.

Time: 8:30 AM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Bethesda Holiday Inn, 8120

Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Syed M. Amir, Scientific

Review Administrator, Center for Scientific

Review, National Institutes of Health, 6701

Rockledge Drive, Room 6168, MSC 7892,

Bethesda, MD 20892, (301) 435–1043,

amirs@csr.nih.gov.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: Surgery, Radiology

and Bioengineering Initial Review Group

Surgery, Anesthesiology and Trauma Study

Section.

Date: February 14–15, 2000.

Time: 1:00 PM to 4:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Georgetown Holiday Inn, Mirage I

Room, 2101 Wisconsin Avenue, Washington,

DC 20007.

Contact Person: Gerald L. Becker,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5114,

MSC 7854, Bethesda, MD 20892, (301) 435–

1170.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333,

93.337, 93.393–93.396, 93.837–93.844,

93.846–93.878, 93.892, 93.893, National

Institutes of Health, HHS)

Dated: January 28, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–2627 Filed 2–4–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Glycoprotein Hormone

Superagonists

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 09/185,408 filed

May 6, 1996 entitled ‘‘Glycoprotein

Hormone Superagonists’’, to

EndocrinoLogiz, Inc., having a place of

business in Princeton, NJ 08542. The

contemplated exclusive license may be

limited to use for human therapeutics

and diagnostics. The United States of

America is the assignee of the patent

rights in this invention.

This announcement replaces an

earlier Federal Register notice (64 FR

38685, July 19, 1999) which is hereby

withdrawn.

DATES: Only written comments and/or

application for a license which are

Federal Register / Vol. 65, No. 25 / Monday, February 7, 2000 / Notices 5879

received by the NIH Office of

Technology Transfer on or before April

7, 2000, will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Charles Maynard,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7056, ext. 243; Facsimile: (301) 402–

0220; e-mail: CM251N@NIH.GOV.

SUPPLEMENTARY INFORMATION: This

invention relates generally to modified

glycoprotein hormones and specifically

to modifications to a human

glycoprotein, which create superagonist

activity. Glycoprotein hormones

comprise a family of hormones, which

are structurally related heterodimers

consisting of a species common α subunit and a distinct β sub-unit that

confers the biological activity for each

hormone. However, this invention is not

limited to specific hormones, specific

subjects such as humans as well as nonhumans mammals, specific amino acids,

specific clinical conditions, specific

analogs, or specific methods.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: February 1, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–2630 Filed 2–4–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Nitroxides as Protectors

Against Oxidative Stress and in the

Prophylactic and Therapeutic

Treatment of Aging, Obesity and

Cancer

AGENCY: National Institutes of Health,

Public Health Service, DHHS

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 07/494,532, filed

March 16, 1990, entitled ‘‘Nitroxide as

Protectors Against Oxidative Stress’’

and U.S. Patent Application Serial No.

60/047,724 filed May 27, 1997 entitled,‘‘

The use of Nitroxides in the

prophylactic and therapeutic treatment

of cancer due to genetic defects’’ and

corresponding foreign patent

applications to Mitos, Inc., having a

place of business in San Diego,

California. The patent rights in these

inventions have been assigned to the

United States of America.

The contemplated exclusive license

may be limited to the use compounds

and methods disclosed and claimed in

the invention for the prevention and

treatment of obesity, cancer and the

amelioration of the direct effects of

aging.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before May 8,

2000, will be considered.

ADDRESSES: Requests for a copy of the

patent application, inquires, comments

and other materials relating to the

contemplated license should be directed

to: Norbert J. Pontzer, J.D., Ph.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7736, ext. 284; Facsimile: (301) 402–

0220; E–mail: np59n@nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent application.

SUPPLEMENTARY INFORMATION: New

metal-independent nitroxide

compounds are anti-oxidants capable of

protecting cells, tissues, and organs

against the harmful effects of toxic

oxygen related species (hydroxyl

radical, hydrogen peroxide, superoxide).

The toxic oxygen related species have

been implicated in cancer and aging.

These nitroxides slow the death rate in

experimental animals with cancers

caused by deletion of the p53

suppressor gene. These nitroxides also

cause weight loss in mice with no

apparent toxicity.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 90 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: January 31, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–2631 Filed 2–4–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Nitroxides as Protectors

Against Oxidative Stress and the

Prophylactic and Therapeutic

Treatment Radiation Damage to

Normal Tissue

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 07/494,532, filed

March 16, 1990, entitled ‘‘Nitroxides as

Protectors Against Oxidative Stress’’

and U.S. Patent Application Serial No.

60/047,724 filed May 27, 1997 entitled,